creat bluematrix
novo pioneer deliv cv result oral
messag novo buy dkk report top line result
pioneer cv safeti studi oral semaglutid achiev non-inferior
reduct advers cardiovascular event mace view result
consist overal class leader novo ozemp victoza
lli trulic statist signific reduct cv death all-caus
mortal demonstr oral semaglutid short durat valid posit
view novo semaglutid franchis overal class
oral semaglutid file plan inclus cv clinic data label would
upsid expect novo expect file oral semaglutid regulatori review
us eu first half still unclear whether mgmt
announc plan includ pool cv data differ formul semaglutid
sustain pioneer clinic data section oral sema ozemp
clear us clinic meaning benefit semaglutid demonstr date
remain posit novo long-term growth expect categori
initi coverag
oral semaglutid result consist semaglutid efficaci
cardiovascular outcom trial cvot trial complet drug class
seven cvot studi includ recent posit top-line result
lli buy surpris us result pioneer
short durat studi month median follow time vs typic
year cv outcom studi rel small number mace event
even though mace benefit wasnt statist signific overal benefit oral
semaglutid consist class direct hazard ratio benefit favor
oral semaglutid compar mace composit hr victoza
tanzeum ozemp given result wed
expect larger longer-dur studi oral semaglutid reach statist signific
compar oral antidiabet agent oral semaglutid compar favor well
class drug jardianc mace composit benefit statist
signific studi larger patient median follow-up
year pioneer oral semaglutid demonstr statist signific result
cardiovascular death hr all-caus mortal hr
respect cv outcom trial total date jardianc empa-
victoza leader demonstr benefit cardiovascular all-caus
page analyst certif import disclosur
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst research associ receiv compens base upon variou factor includ qualiti research investor client
feedback guggenheim secur llc overal revenu includ invest bank revenu
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
rate price target histori novo nordisk a/ novob dc
creat bluematrix
buy describ stock expect provid total return price appreci plu yield within period
neutral describ stock expect provid total return price appreci plu yield plu minu within
sell describ stock expect provid total neg return price appreci plu yield within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/or
cs coverag suspend guggenheim secur llc suspend coverag compani
nc cover guggenheim secur llc cover compani
monitor describ stock whose compani fundament financi monitor financi project opinion
invest merit compani provid
review ur follow releas signific news compani rate temporarili place review suffici
inform obtain assess analyst
guggenheim secur llc methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ restrict analys
market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash flow ev/ebitda price-to-earnings pe/growth
price-to-cf p/fcf premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
price target assign buy- sell-rat stock price target neutral-r stock provid discret analyst
equiti valuat risk valuat methodolog risk associ cover compani price target cover compani pleas
see recent company-specif research report http //guggenheimlibrari bluematrix com/client/librari jsp contact primari analyst
guggenheim secur llc repres email
page analyst certif import disclosur
